Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Search
IASLC.org
IASLC Lung Cancer News
Home
Science & Medicine
Diagnostic Oncology
Evolving Standards of Care
FDA Corner
Global Initiatives
Immunotherapy
Lung Cancer Screening
NCI Corner
Pathology
Prevention and Tobacco Control
Radiation Oncology
Supportive Care
Targeted Therapy
Advocacy & Survivorship
Thought-Leader Perspective
Allied Health
Meetings
Highlights
Preview
News
Breaking News Briefs
In Memoriam
People
Home
Authors
Posts by lungcanc
lungcanc
526 POSTS
0 COMMENTS
PACIFIC Trial Leads to Durvalumab Approval in United States
lungcanc
Barriers to Access to New Lung Cancer Drugs in Latin America
lungcanc
Q&A with the New IASLC President
lungcanc
Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint...
lungcanc
Laurie E. Gaspar, MD, MBA
lungcanc
Radon: A Modifiable Lung Cancer Risk Factor
lungcanc
European Union Position Statement on Lung Cancer CT Screening: The Next...
lungcanc
Paolo Paoletti, MD
lungcanc
The Upcoming Lung Cancer Neoadjuvant Meeting
lungcanc
Targeted Therapies Meeting Focuses on Upcoming Research Advances in Lung Cancer
lungcanc
1
...
27
28
29
...
53
Page 28 of 53
Meeting News
Leora Horn, MD – IASLC Virtual Presidential Symposium Presentation
Paul Baas, MD – IASLC Virtual Presidential Symposium Presentation
TRACERx Data Show That Tracking MRD With ctDNA Heralds Disease Relapse
cfDNA Analysis Suggests EML4-ALK Variant Does Not Influence Response to Lorlatinib
Load more
Edit with Live CSS
